Abatacept may reduce graft-versus-host disease after hematopoietic stem cell transplantation – 3.22.2018 – Healio
The addition of abatacept to standard therapy reduced the incidence of severe acute graft-versus-host disease to less than 5%, according to phase 2 study results presented at ASH Annual Meeting and Exposition. Incidence of grade 3 or grade 4 GVHD decreased from 32% to 3% among patients who underwent mismatched unrelated donor stem cell transplants for advanced malignancies and received standard prophylaxis plus abatacept in the posttransplantation setting, according to Dr. Leslie Kean, associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.
Trial to assess dual CAR T-cell therapy for children, young adults with leukemia – 3.11.2018 – HemOnc Today
A trial is underway to evaluate the use of dual chimeric antigen receptor T-cell immunotherapy for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia. Dr. Rebecca Gardner, attending physician in the department of pediatric hematology-oncology at Seattle Children’s Hospital, and colleagues aim to reprogram CAR T cells to detect and destroy leukemia cells by targeting both the CD19 and CD22 proteins upfront. If the cancer evolves to no longer express CD19, the CAR T cells can still attack the cancer through the identification of the CD22 protein. HemOnc Today spoke with Gardner about the study, the rationale for this dual-targeting approach and the benefits it may confer.
In the future, cancer treatment may be remote controlled – 2.6.2018 – Healthline
In the future, fighting cancer may no longer mean grueling chemotherapy, but genetically altered immune systems that can be “remote controlled.” That’s currently the hope of researchers based at the University of California, San Diego, who are investigating if ultrasound waves can manipulate immune system T cells to effectively create a new form of cancer treatment. Dr. Rebecca Gardner, an oncologist at Seattle Children’s Hospital, said this study is a “pretty nifty idea.” “What’s really unique about this study is that it’s anatomically specific,” said Gardner, who’s also a principal investigator of two CAR T-cell immunotherapy clinical trials at Seattle Children’s. “You have to have the ultrasound machine that goes to where the CAR T cells are and turns them on only in that location.”